Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...
Amgen brings back its imaginary ambulance workers in a new TV ad for cholesterol fighter Repatha, but the latest spot adds dancing and disco music—and eases up on the foreboding—to lighten the mood.
Most commercial insurance plans and Medicare Part D plans cover Repatha, and Medicare Advantage (Part C) plans with drug coverage may also cover it. To find out if your Medicare Advantage or Part D ...
The scale of spending differences among these three markets reflects the straightforward demographic reality that Repatha’s core cardiovascular population skews heavily toward Medicare-aged adults, ...
Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results